Table 1.
Subject characteristics.
Table 2.
Hemodynamic and clinical endpoints for IPAH subjects.
Figure 1.
Representative gas chromatograms from a control subject (black line) and IPAH subject (grey line) (A) showing significantly different (p≤0.05) unique peaks for the control subject (B) and IPAH subject (C).
An example of a head-to-tail comparison of an experimental mass spectrum (D) of one of the identified significantly different peaks unique for the IPAH group at a retention time of 81.436 min. (top) with a NIST/Wiley 2009 database search hit (bottom) identifying N-ethyl-Benzeneamine as giving the best match for the experimental spectrum.
Figure 2.
Plot of the results of autoregression and partial least squares analysis-weighted components of control subjects (dark circles) and IPAH subjects (open squares).
22 out of 27 disease (positive) samples were confirmed as positive (sensitivity = 81.5%) and 21 out of 30 control (negative) samples were confirmed as negative (specificity = 70.0%). The positive likelihood ratio was 2.76 while the negative likelihood ratio was 0.368.
Table 3.
Chemicals identified with “high confidence” for peaks found in all groups.
Figure 3.
Plots of step-wise linear regression analysis of actual vs. predicted values for mPAP, PVR, and PAWP.
There were significant associations between mPAP and peak heights at retention times of 90.733 and 96.547 minutes (A); PVR and peak heights at retention times of 90.733, 96.547 and 238.247 minutes (B); PAWP and peak heights at retention times of 67.380 and 118.995 minutes (C).
Table 4.
Correlations with pulmonary hemodynamic variables.